Valuation : PTC Therapeutics, Inc.

Market Cap 5.89B 5.08B 4.78B 4.35B 8.19B 559B 8.23B 56.49B 21.99B 284B 22.11B 21.63B 943B P/E 2026 *
46.1x
P/E 2027 * 26.1x
Enterprise Value 4.02B 3.47B 3.26B 2.97B 5.59B 381B 5.62B 38.54B 15B 194B 15.09B 14.76B 643B EV / Sales 2026 *
3.2x
EV / Sales 2027 * 2.73x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : PTC Therapeutics, Inc.

1 day+1.47%
1 week-3.96%
Current month+1.47%
1 month+3.75%
3 months-4.39%
6 months+3.48%
Current year-7.11%
1 week 68.76
Extreme 68.755
72.66
1 month 66.07
Extreme 66.07
75
Current year 61.43
Extreme 61.43
90.87
1 year 52.43
Extreme 52.43
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 2023-03-21
Director of Finance/CFO 41 2023-07-12
Chief Tech/Sci/R&D Officer - 2017-09-30
Director TitleAgeSince
Chairman 74 2004-10-31
Chairman 80 1998-03-30
Director/Board Member 65 2005-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/27/26
Section Six Partners
SellCompany -12,500 0.0151%
8/26/26 Other

Chairman

0 0%
8/20/26
Section Six Partners
SellCompany -12,500 0.0151%
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%-3.96%+43.04%+76.05% 5.8B
+0.28%-5.97%+58.34%+108.22% 1,031B
+2.01%-0.71%+53.07%+68.99% 641B
+1.39%-2.18%+23.57%+75.43% 453B
-1.50%-7.04%+33.55%+33.94% 349B
+6.25%+2.04%+28.97%+46.57% 290B
-0.07%-4.12%+0.95%+11.79% 252B
+1.92%-0.93%+52.28%+70.67% 232B
+0.51%-4.52%-19.50%-54.83% 201B
+2.45%+0.77%+32.71%+95.59% 181B
Average +1.60%-2.83%+30.70%+53.24% 363.56B
Weighted average by Cap. +1.60%-3.40%+38.39%+66.41%

Financials

2026 *2027 *
Net sales 1.26B 1.08B 1.02B 928M 1.75B 119B 1.75B 12.04B 4.69B 60.61B 4.71B 4.61B 201B 1.37B 1.18B 1.11B 1.01B 1.9B 130B 1.91B 13.14B 5.11B 66.12B 5.14B 5.03B 219B
Net income 144M 124M 117M 107M 201M 13.69B 202M 1.38B 539M 6.96B 542M 530M 23.09B 216M 187M 176M 160M 301M 20.54B 302M 2.08B 808M 10.45B 812M 795M 34.64B
Net Debt -1.87B -1.61B -1.52B -1.38B -2.6B -178B -2.62B -17.95B -6.99B -90.33B -7.03B -6.87B -300B -2.15B -1.85B -1.74B -1.59B -2.98B -204B -3B -20.58B -8.01B -104B -8.05B -7.88B -343B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
26-09-01 US$70.56 +1.47% 691,014
26-08-31 US$69.54 -0.78% 841,097
26-08-28 US$70.09 -2.40% 692,675
26-08-27 US$71.81 -1.21% 746,330
26-08-26 US$72.69 -1.06% 533,667
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
70.56USD
Average target price
99.29USD
Spread / Average Target
+40.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock